4.7 Review

How I treat paroxysmal nocturnal hemoglobinuria

Journal

BLOOD
Volume 113, Issue 26, Pages 6522-6527

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2009-03-195966

Keywords

-

Categories

Funding

  1. National Institutes of Health [CA70970]

Ask authors/readers for more resources

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal blood disorder that manifests with hemolytic anemia, bone marrow failure, and thrombosis. Many of the clinical manifestations of the disease result from complement-mediated intravascular hemolysis. Allogeneic bone marrow transplantation is the only curative therapy for PNH. Eculizumab, a monoclonal antibody that blocks terminal complement activation, is highly effective in reducing hemolysis, improving quality of life, and reducing the risk for thrombosis in PNH patients. Insights into the relevance of detecting PNH cells in PNH and other bone marrow failure disorders are highlighted, and indications for treating PNH patients with bone marrow transplantation and eculizumab are explored. (Blood. 2009; 113: 6522-6527)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available